NLS Pharmaceutics Ltd. - NLSP EV/EBITDA Multiple

NLS Pharmaceutics AG (NLSP) drug distribution relies on strictly controlled transportation to eliminate theft. Growth prospects are tied to upcoming clinical trial stages for insomnia treatments, while investors have already priced in the current shortage of medications. The market dynamics reflected in the quotes on GURU.Markets show an EV/EBITDA of , confirming the potential for pricing power driven by the unique stimulant Mazindol for narcolepsy therapy.

NLSP (NLS Pharmaceutics Ltd.) EV/EBITDA Multiple history from 07/04/2022 to 11/12/2026

NLSP (nlspharma.com): analytical breakdowns and indicator data

- market price and analyst price targets:

Price Chart NLS Pharmaceutics|NLSP - Broker Consensus Forecast

- issuer market value details:

Market Capitalization NLS Pharmaceutics|NLSP - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share NLS Pharmaceutics|NLSP - Book Capitalization|Market Value to Book Value Ratio nlspharma.com|NLSP - Aggregate Asset Value

- debt and liquidity data:

- net income and valuation multiples indicators:

NLSP - Company Net Income|Expected Profit NLS Pharmaceutics AG|NLSP - Price to Earnings Multiple|Future Price to Earnings NLS Pharmaceutics|NLSP - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharmaceutics|NLSP - Operating income before deduction of amortization|Net earnings per share for the last 12 months NLS Pharmaceutics|NLSP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months nlspharma.com|NLSP - Earnings per share trend in current year|Earnings growth forecast for next year NLS Pharmaceutics AG

Summary company analytics:NLSP (NLS Pharma)

NLS Pharmaceutics AG (NLSP) is investing in the development of innovative drugs for the treatment of ADHD and narcolepsy, which requires significant capital expenditures. The EV/EBITDA multiple trend compares the total market value of the business, including debt, to its operating profit before interest, taxes, depreciation, and amortization. The stability of this chart confirms a resilient valuation, although a stagnant indicator may signal an undervaluation of the R&D assets' potential.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc. (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Therapeutics CTNM|Larimar Therapeutics Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CAPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entrada Therapeutics, Inc|PTHS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple MediciNova MNOV|Enterprise Value to EBITDA Ratio SER|Company Value to EBITDA BioXcel Therapeutics Inc BTAI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ProMIS Neurosciences (PMN)|apimedsus.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AEON Biopharma, Inc. AEON|Bionomics Ltd. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HUGE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Reata Pharmaceuticals Inc RETA